SPAC IPO Update — October 19, 2026
No SPAC IPOs priced on October 19, 2026; October MTD now stands at 4 IPOs totaling $491M over 19 sessions.
SPAC IPO Count
$ totals include underwriter over-allotment.
| Date | Ticker | Issuer | IPO Size | Trust Funding |
|---|---|---|---|---|
| Oct 16 | TCXB | TCGX Acquisition Corp. II | $100M | 100.0% |
| Oct 14 | FLSC | FRAZIER LIFE SCIENCES ACQUISITION CORP II | $75M | 100.0% |
Daily SPAC Update — October 19, 2026
SPAC DEALS ANNOUNCED
October 19 | Tcgx Acquisition Corp (TCGX) + TriGemX BioTriGemX Bio is a biotechnology company developing elismetrep, a potential first-in-class TRPM8 channel blocker aimed at treating migraines. The company’s research focuses on neural signaling pathways, particularly targeting the trigeminal ganglion, where TRPM8 is expressed. Elismetrep is currently undergoing Phase 3 trials for acute migraine treatment, with initial results expected in mid-2027.
October 15 | Pyrophyte Acquisition Corp II (PAII) + Sakuu CorpSakuu Corp provides commercial-scale printing equipment and technologies for manufacturers of batteries, electrodes, and supercapacitors. Its Kavian Platform enables dry printing of battery electrodes, promoting rapid manufacturing while reducing costs and waste. Headquartered in Silicon Valley, it focuses on sustainable manufacturing solutions.
EXTENSION VOTES
TEXAS VENTURES ACQUISITION III CORP (TVA)vote -> extend from October 24, 2026 to July 24, 2027
ASPAC III ACQUISITION CORP (ASPC)vote October 19, 2026 -> extend from November 12, 2026 to November 12, 2028
SPAC EXTENSIONS
BAYVIEW ACQUISITION CORP (BAYA) * Extension FilingBayview Acquisition Corp extends its business combination deadline by one month, funding the extension with $50,000.
OTHER SPAC NEWS
OAKTREE ACQUISITION CORP III LIFE SCIENCES (OACC) * Vote PostponedOaktree Acquisition Corp. III Life Sciences postpones the general meeting to Oct 23, 2026 to extend the business combination deadline.
SPAC Executive & Director Moves — October 19, 2026
| Company | Ticker | Moves |
|---|---|---|
| AVERIN CAPITAL ACQUISITION CORP | ACAA |
|
SPAC Movers — October 19, 2026
| Company | Ticker | Change | Price | Stage |
|---|---|---|---|---|
| FUTURE VISION II ACQUISITION CORP | FVN | 16.3% | $ 11.05 | Announced |
| ARCHIMEDES TECH SPAC PARTNERS II CO | ATII | 4.9% | $ 9.29 | Announced |
| QUETTA ACQUISITION CORP | QETA | 3.1% | $ 11.55 | Announced |
| SILVERBOX CORP IV | SBXD | 2.6% | $ 11.39 | Announced |
| BEST SPAC I ACQUISITION CORP | BSAA | 1.2% | $ 10.99 | Announced |
| Company | Ticker | Change | Price | Stage |
|---|---|---|---|---|
| BLACK HAWK ACQUISITION CORP | BKHA | -12.3% | $ 6.01 | Announced |
| RF ACQUISITION CORP II | RFAI | -10.0% | $ 30.59 | Announced |
| XFLH CAPITAL CORP | XFLH | -7.3% | $ 10.09 | Pre-Deal |
| RIBBON ACQUISITION CORP | RIBB | -6.2% | $ 6.20 | Announced |
| RISING DRAGON ACQUISITION CORP | RDAC | -6.1% | $ 4.89 | Announced |
Frequently Asked Questions
-
What did Tcgx Acquisition Corp (TCGX) announce on October 19, 2026?Tcgx Acquisition Corp (TCGX) announced a merger with TriGemX Bio, a biotechnology company focused on neural signaling pathways and migraine treatment.
-
What is TriGemX Bio developing?TriGemX Bio is developing elismetrep, a potential first-in-class TRPM8 channel blocker for acute migraine treatment. Initial Phase 3 results are expected in mid-2027.
-
How many SPAC IPOs priced in October 2026 through October 19?4 SPAC IPOs priced for $491M through the first 19 days of October 2026, including over-allotment, versus 3 IPOs for $538M over the same span in September.
-
Which extension votes were held on October 19, 2026?
-
When is Oaktree Acquisition Corp. III Life Sciences (OACC)’s postponed meeting?Oaktree Acquisition Corp. III Life Sciences (OACC) postponed its general meeting to October 23, 2026 to vote on extending its business-combination deadline.